In this era of technology-driven global neuroscience initiatives, the role of the neurotechnology industry remains woefully ambiguous. Here, we explain why industry is essential to the success of these global initiatives, and how it can maximize the scientific impact of these efforts by (1) scaling and ultimately democratizing access to breakthrough neurotechnologies, and (2) commercializing technologies as part of integrated, end-to-end solutions that accelerate neuroscientific discovery.
The Role of the Neurotechnology Industry in the Global Brain Initiatives Remains Undefined This is a time of unprecedented opportunity for discovery in neuroscience. Today, powerful tools and technologies, from monosynaptic tracers, to optical technologies for large-scale activity monitoring and manipulation, to machine-learning algorithms for pattern extraction, have opened the floodgates to fundamental insights about brain structure, function, and disorder (Callaway and Luo, 2015; Deisseroth and Schnitzer, 2013) . The necessity of technological innovation in powering scientific discovery is being increasingly acknowledged by the neuroscience community and has encouraged governments across the world to launch large-scale brain research efforts, most notably, the Human Brain Project (E.C.), the BRAIN Initiative (U.S.), the Brain/ MINDS Project (Japan), and the China Brain Project. These and other nascent national projects and the recent efforts to foster co-operation between them are heralding an exciting era of truly global neuroscience (http://www.rockefeller. edu/research/intercenter/globalbrain).
In the U.S., the Presidential BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative has focused its efforts on the development and application of technologies for a comprehensive mechanistic understanding of the brain at the level of circuits and networks (https://www.braininitiative.nih. gov/pdf/BRAIN2025_508C.pdf). Since its launch 3 years ago, the BRAIN Initiative has consistently sought to be an exemplar of public-private partnership, with scientific philanthropies, private research institutions, disease foundations, and a few large technology companies, acting as force multipliers for the efforts of the federal agencies in advancing the goals of this ambitious endeavor (https:// www.whitehouse.gov/sites/default/files/ microsites/ostp/brain_fact_sheet_9_30_ 2014_final.pdf). However, it is truly ironic that for the BRAIN Initiative, which places neurotechnology front and center, with a few exceptions, the one stakeholder that is largely absent is the neurotechnology industry itself. This is certainly not for the lack of desire or efforts to co-opt the industry by the federal agencies and the leadership of the BRAIN Initiative. The reasons for this anomaly are complex and span from constrained resources to misalignment of incentives and overall unclear expectations of industry. These challenges are further compounded by the heterogeneous nature of the corporates that make up the neurotechnology industry, from discovery phase ''tools and technology'' companies like Inscopix to clinically oriented companies in the pharma, biotech, devices, and digital therapeutic sectors. While companies across this spectrum can create profound and unique value for BRAIN and other international projects, it is the tools and technology sector that is most directly aligned with their core scientific mission today and thus most organically incentivized to support it.
Our brief was to write this essay from our perspective as a private-sector partner of the BRAIN Initiative and from our experiences and challenges in building a 21 st century neuroscience company.
Here, we explain how the small but burgeoning tools and technology sector can make a disproportionate impact on advancing neuroscientific discovery by embarking on a technological development and scaling mission that is both thoughtful and long term in its objectives. We then highlight the strategic reasons for a robust partnership between the global brain initiatives and the tools and technology sector and how each stands to benefit from it.
Scaling Access to Breakthrough Neurotechnologies through Iterative Refinement
Technological innovation remains a significant focus of the BRAIN Initiative. However, technological innovation, while absolutely necessary, is completely insufficient for catalyzing brain research and must be accompanied by scalable technological dissemination. Its importance is hard to overstate. The only way to unleash the inherent value of transformative technologies is to make them accessible to the widest spectrum of researchers in a reliable manner. Consider how widespread access to multielectrode arrays, two-photon microscopy systems, and optogenetics, have transformed our understanding of the neural circuit basis of brain function and behavior (Baker, 2010; Deisseroth and Schnitzer, 2013) . The technologies that are emerging from the BRAIN Initiative are diverse and range from transgenic animals, to sophisticated instrumentation, to computational tools (https://www.braininitiative. nih.gov/funding/fundedAwards.htm). It is of utmost importance that scalable dissemination for each is achieved through appropriate mechanisms, keeping the principles of democratic access and reproducible science in sharp focus. Software-based tools for data processing and analysis are quite amenable to dissemination through open source models, provided there are organized means to support a user community and to embrace a developer community. On the other hand, scaling and organized dissemination of advanced instrumentation has historically only been achieved successfully through direct commercialization to individual laboratories, institutional centers, and core facilities (Alivisatos et al., 2015) .
To understand why industry is uniquely positioned to maximize the scientific impact of the BRAIN Initiative by scaling access to breakthrough neurotechnologies, it is important to first understand the comparative advantages that academia and industry bring to the process of technological development. Individual investigators in academia and research institutions whose research focus is to develop new technologies (and methods) are most directly incentivized to undertake high-risk innovation and invent breakthrough technologies for neuroscience research. Many of these fledgling technologies are promising, yet might languish in the laboratories that they were invented in never to be incorporated into routine neuroscience practice. This happens, in part, because individual investigator-led innovations are not designed for scalable manufacturing, consistent performance, and broad usability. It is here that the tools and technology sector can deliver on the promise of technology scaling by not only fulfilling its obligatory role in manufacturing components at scale, precision, and cost, but going beyond it, iteratively refining and improving nascent technologies.
Disciplined iterative refinement through application of industrial engineering principles is key to migrating potentially breakthrough technologies from a proof-ofconcept or early prototype stage into mature research products. Industry is better suited and better incentivized to perform this necessary and tedious task than academia for several reasons, including the recurring business opportunities that it generates. However, for this era of technological development for neuroscience, which is increasingly based on investigating the intact and living nervous system, close partnership between the industry and the researcher community is paramount because thoughtful iterative refinement is really a user-centric approach to product development, one that employs tight feedback loops across a wide range of applications to keep improving technologies for usability and enhanced capability.
The importance of close co-operation between these two stakeholders is further bolstered by our own experience in commercializing the patented miniature microscope technology that we invented at Stanford University for in vivo calcium imaging. An important lesson from this endeavor is that the path to successful and sustainable scaling of technological access usually commences with a decidedly controlled phase of testing, validation, and iterative refinement of new promising technologies with a select group of expert investigators. These early-adopter laboratories are typically well funded, possess the requisite domain knowledge and technical expertise, are comfortable working with immature technologies, and most importantly, provide critical feedback that drives the iterative refinement process forward. The immense value that this cohort creates in exchange for receiving early technological access should not be underestimated, for it is they who effectively subsidize the technological development process and it is they who de-risk the scalable dissemination of new technologies through peer-reviewed scientific publications for the entire neuroscience research community.
Commercializing Breakthrough Neurotechnologies through ''Integrated Solutions''
Another important lesson that we draw from our commercialization experience is that making technologies mature through iterative refinement only takes the scaling process so far in the prevailing singleinvestigator-led model of neuroscience research. Today, only a small segment of researchers can take full advantage of the unfolding technological revolution in neuroscience for the simple reason that while modern neuroscience is increasingly transdisciplinary in nature, the training and expertise of individual investigators is splintered by its sub-disciplines. Today, we are largely a community of molecular, systems, computational, or behavioral neuroscientists, of experimentalists or theorists. If neuroscience is to be a field that genuinely fosters an integrated understanding of the brain across scales and levels, from genes to circuits to behavior, then the silos within the field must be permeabilized and, in addition, the field as a whole must be able to attract top investigators from other scientific disciplines.
While the onus for this rests primarily with the neuroscience research community and the funding agencies, industry can play an important role in lowering the barriers by integrating different types of tools and technologies, biological reagents, instrumentation, associated consumables, and neuroinformatics, along with training and scientific support, into turnkey ''solutions'' for supporting specific avenues of scientific discovery. This approach naturally builds upon the industry's value proposition of scale, speed, and standardization for scientific discovery and certainly forms the core of our longterm business strategy. The success of companies like Illumina, which have employed a similar approach for genomics, provides precedent and a measure of validation for the pivotal role that standardized industrial solutions, subjected to a rigorous quality control regime, can play in accelerating scientific discovery by decades. They foster not only broad-based adoption of new technologies, but also reproducibility of scientific discoveries.
Integration of constituent tools, technologies, and services, into solutions goes well beyond their simple aggregation or concatenation. It is really a holistic approach that involves making each constituent compatible with the other in a manner such that the entire solution is optimized for performance. This of course requires high quality and sustained R&D efforts, and top-notch scientific talent to provide the follow-on training and support services, which escalates total costs well beyond the cost of manufacturing products at scale. The value derived to the neuroscience research community through this integrated solutions approach is of course far greater than the total costs incurred to them. However, the strong tradition of individual ''science-driven'' laboratories building their own tools through artisanal approaches poses a central challenge for this approach. Beyond impacting our sector, this has significant opportunity costs for the entire neuroscience research enterprise, from sub-optimal use of resources in a tight funding environment to the catalysis and reproducibility of scientific results.
The tools and technology sector must lead from the front and employ every entrepreneurial mechanism, conventional and unconventional, to broaden access to promising technologies and to dampen the culture of ''artisanal neuroscience'' by propagating integrated solutions. One nascent effort on our part, which shows promise for easily shippable technologies is the subscription-based ''Technologyas-a-Service'' model routinely employed by software and cell-phone companies. This model appears to be particularly suited for this era of rapid and iterative technological development, not only from a commercial perspective, but also from the researcher's perspective, giving them affordable access to latest versions of technologies through continuous upgrades, and the flexibility to scale up (and down) their technological capacity as per their experimental needs. From our vantage point in Silicon Valley, there are many innovative business models employed by other sectors of the economy, and our sector should borrow, adapt, and test them to the benefit of neuroscience research.
The Tools and Technology Sector as an Integral Partner for BRAIN and Other International Initiatives The BRAIN Initiative and other international projects are perhaps the most audacious scientific endeavors ever to be undertaken by humanity. The need for historic levels of co-operation and co-ordination between the different stakeholders is best echoed in President Obama's ''all hands on deck'' call to action for the BRAIN Initiative in 2014 (https://www.whitehouse.gov/blog/2014/ 02/24/white-house-call-action-advancebrain-initiative), and in the deliberations of the ''Coordinating Global Brain Projects'' meeting held at Rockefeller University in September 2016 (http:// www.rockefeller.edu/research/intercenter/ globalbrain). However, impactful co-operation and collaboration will only arise when each stakeholder sees the value in it.
The tools and technology sector stands to benefit directly by supporting and partnering with the global brain initiatives because they finance and catalyze highrisk, cutting-edge technological innovations, which can possibly be commercialized into game-changing products for neuroscience research. The primary reason why companies in our space do not feel incentivized to participate in these initiatives is because they rarely get an opportunity to directly see or shape the incentives. As BRAIN and other initiatives make progress and evolve, this can change by giving the tools and technology sector a formal seat at the table as part of multi-stakeholder deliberations in defining, evaluating, and refining their scientific, technological, dissemination, and training objectives. This has the potential to show the industry that a virtuous circle can be created in a way that benefits it too.
Active partnering and alignment of the tools and technology sector with BRAIN and other international initiatives will also create several strategic benefits for the latter. First, the aforementioned activities of our sector in technological development and scaling will help generate broad-based support for the initiatives by making their raison d'ê tre and benefits tangible to the larger neuroscience community. Second, the end-goal of these technology-driven brain projects is truly transformative knowledge about the brain. This will likely take decades to emerge, but the tools and technology sector brings clear value in accelerating the path to that transformative knowledge. And last, support and alignment of ''radical science'' tools and technology companies, many of which emerge from federally funded basic research, coupled with the potential of our sector in generating across the spectrum economic activity, bodes well for sustained federal and other investments in the initiatives and for curiosity-driven neuroscience.
The early technological breakthroughs emerging from the BRAIN Initiative, and the underlying spirit of co-operation at the ''Coordinating Global Brain Projects'' meeting has created new momentum for the global brain projects and the neurotechnology industry to actively partner with each other, and to advance neuroscience research for the benefit of all.
